El-Gazzar et al. reported that NK cell cytotoxicity was enhanced after treatment with a DR5 agonist antibody, which resulted in higher expression of DR5 in an ovarian cancer mouse model [27]. This evidence concerns the gene TNFRSF10B and ovarian carcinoma.